🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Comparing Efficiency of Mirogabalin and Pregabalin in Primary TKA

RecruitingNAAges 50 Years - 85 YearsAllThammasat University Hospital
NCT06328062 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this RCT is to compare efficacy between mirogabalin and pregabalin in pain reducing after unilateral primary total knee arthroplasty. The main question\[s\] it aims to answer are: • Does mirogabalin have better pain reduction than pregabalin after unilateral primary total knee arthroplasty. Participants will randomized to mirogabalin or pregabalin group and will take the drug for 2 weeks after TKA. Researchers will compare to pregabalin group to see pain and functional outcomes after TKA.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age 50-85 years old 2. Unilateral primary osteoarthritis undergoing primary TKA 3. ASA I-III Exclusion Criteria: 1. GFR \<60 2. Allergy to drug in this study 3. Cannot underwent spinal anesthesia and adductor canal block 4. Taking gabapentinoid within 3 months before surgery 5. History of previous knee surgery 6. Severe liver disease
💊

What it tests

  • Mirogabalin
  • Pregabalin
📍

Where

1 site
Thammasat University Hospital
Khlong Luang, Thailand
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy